Alemtuzumab & MS

A few days ago (April 15th 2010), Medical News Today reported on the use of Alemtuzumab for the treatment of MS. The research in question reported that a significant percentage of MS patients who received Alemtuzumab remained free of clinically-active disease.

More precisely, 71% of the patients treated with alemtuzumab remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

This trial was compared Alemtuzumab to Rebif® (interferon beta-1a) in patients with early, active, and relapsing-remitting MS, who had received no prior therapy. For the details of the trial and more on the results visit the Medical News Today website link to the right ; )

What I think is important to highlight from this trial is that researchers believe Alemtuzumab to target the immune system cells responsible for the cellular damage (found in multiple sclerosis), while sparing other immune system elements.


1 Comment (+add yours?)

  1. gavalon
    Jul 27, 2010 @ 17:26:59

    Hi, I don’t know if this will be of interest to you, but I’ve just finished writing a little bit about the history of Campath.
    If you have the time I’d be interested in any thoughts you may have on it.


Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: